The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria
Published in
British journal of dermatology, vol. 148, no. 3, p. 604-606Publication date
2003Keywords
- Adult
- Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
- Chronic Disease
- Cyclooxygenase Inhibitors/*therapeutic use
- Female
- Histamine Release/drug effects
- Humans
- Lactones/*therapeutic use
- Male
- Middle Aged
- Sulfones
- Urticaria/*drug therapy
UNIGE affiliation entities
Citation (ISO format)
BOEHNCKE, Wolf-Henning et al. The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria. In: British journal of dermatology, 2003, vol. 148, n° 3, p. 604–606. doi: 10.1046/j.1365-2133.2003.05209_12.x
Main files (1)
Article
Identifiers
- PID : unige:29787
- DOI : 10.1046/j.1365-2133.2003.05209_12.x
- PMID : 12653769
